Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency

[1]  L. Klomp,et al.  Novel mutations in 3‐phosphoglycerate dehydrogenase (PHGDH) are distributed throughout the protein and result in altered enzyme kinetics , 2009, Human mutation.

[2]  T. Koning.  Treatment with amino acids in serine deficiency disorders , 2006, Journal of Inherited Metabolic Disease.

[3]  M. Durán,et al.  Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: Outcome of treatment with amino acids , 2002, Journal of Inherited Metabolic Disease.

[4]  K. Swoboda,et al.  V490M, a Common Mutation in 3-Phosphoglycerate Dehydrogenase Deficiency, Causes Enzyme Deficiency by Decreasing the Yield of Mature Enzyme* , 2002, The Journal of Biological Chemistry.

[5]  V. Ramaekers,et al.  Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings. , 2001, Neuropediatrics.

[6]  M. Knaap,et al.  Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency. , 2000, Neuropediatrics.

[7]  E. Schaftingen,et al.  3‐phosphoglycerate dehydrogenase deficiency in a patient with West syndrome , 2000, Developmental medicine and child neurology.

[8]  M. Durán,et al.  Beneficial effects of L‐serine and glycine in the management of seizures in 3‐phosphoglycerate dehydrogenase deficiency , 1998, Annals of neurology.

[9]  E. Schaftingen,et al.  3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis. , 1996, Archives of disease in childhood.